Last updated on June 2020

Setmelanotide Phase 2 Treatment Trial in Patients With Rare Genetic Disorders of Obesity


Brief description of study

The purpose of the study is to determine the effect of setmelanotide (RM-493) on weight, hunger assessments and other factors in patients with rare genetic disorders of obesity, including POMC deficiency, LepR deficiency, Bardet-Biedl syndrome and Alstrm syndrome.

Clinical Study Identifier: NCT03013543

Find a site near you

Start Over

Axis Clinical Trials Headquarters

Los Angeles, CA United States
1.97miles
  Connect »

Axis Clinical Trials-Downtown

Los Angeles, CA United States
5.61miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.